Therapeutic use of the encoding sequence of the carboxy-terminal domain of the heavy chain of the tetanus toxin
AssigneesUniversity of Zaragoza, The Autonomous University of Barcelona
InventorsMaría Moreno Igoa, Ana Cristina Calvo Royo, Maria Jesús Muñoz Gonzalvo, Maria Pilar Zaragoza Fernández, Rosario Osta Pinzolas, José Aguilera Avila
Life of this patent
Estimating the term…
Abstract
The present invention relates to the therapeutic use of the carboxy-terminal domain of the heavy chain of the tetanus toxin for the treatment of amyotrophic lateral sclerosis (ALS).
Claims9
A method for ameliorating the symptoms of motor neuron degeneration in a subject with Amyotrophic Lateral Sclerosis (ALS), comprising administering a polypeptide comprising the carboxy-terminal domain of the heavy subunit of the tetanus toxin (HcTeTx) to said subject, wherein:
- (i) the polypeptide comprises the sequence of SEQ ID NO:2 or SEQ ID NO:5 or a fragment thereof;
- (ii) the polypeptide increases the survival of transgenic SOD 1093A mice;
- and,
- (iii) the polypeptide is not a targeting moiety for another therapeutic molecule.
A method for ameliorating the symptoms of motor neuron degeneration in a subject with Amyotrophic Lateral Sclerosis (ALS), comprising administering a polypeptide consisting essentially of the carboxy-terminal domain of the heavy subunit of the tetanus toxin (HcTeTx) to said subject, wherein:
- (i) the polypeptide comprises the sequence of SEQ ID NO:2 or SEQ ID NO:5 or a fragment thereof;
- (ii) the polypeptide increases the survival of transgenic SOD1G93A mice;
- and,
- (iii) the polypeptide is not a targeting moiety for another therapeutic molecule.
A method for ameliorating the symptoms of motor neuron degeneration in a subject with Amyotrophic Lateral Sclerosis (ALS), comprising administering a polypeptide comprising the carboxy-terminal domain of the heavy subunit of the tetanus toxin (HcTeTx), wherein:
- (i) the polypeptide consists of SEQ ID NO:
- 2 or SEQ ID NO:
- 5;
- (ii) the polypeptide increases the survival of transgenic SOD1G93A mice;
- and,
- (iii) polypeptide is not a targeting moiety for another therapeutic molecule.
Dependencies are inferred from the claim text.